Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #25
mi
from
Lynchburg, VA
Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #25
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ashland, OR
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ashland, OR
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
McAllen, TX
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
e-Diary in Heart Failure
The Use of a Symptom and Weight e-Diary Among Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
John Muir Medical Center
mi
from
Concord, CA
e-Diary in Heart Failure
The Use of a Symptom and Weight e-Diary Among Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
John Muir Medical Center
mi
from
Concord, CA
Click here to add this to my saved trials
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wilmington, DE
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilmington, DE
Click here to add this to my saved trials
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Beverly Hills, CA
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Boston University
mi
from
Boston, MA
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve
Derivation and Validation of a Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve
Derivation and Validation of a Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
A Self-Controlled Case Series Study of Fluoroquinolones Exposure and Collagen-related Serious Adverse Events
Status: Enrolling
Updated:  12/31/1969
Janssen Investigative Site
mi
from
Titusville, NJ
A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
A Self-Controlled Case Series Study of Fluoroquinolones Exposure and Collagen-related Serious Adverse Events
Status: Enrolling
Updated: 12/31/1969
Janssen Investigative Site
mi
from
Titusville, NJ
Click here to add this to my saved trials
Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY
Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY
Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
An Open-Label, Randomized, Three-Treatment, Three-Way Crossover Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
An Open-Label, Randomized, Three-Treatment, Three-Way Crossover Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Bio-Kinetic Clinical Applications, Inc.
mi
from
Springfield, MO
Click here to add this to my saved trials
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Jacksonville, FL
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Status: Enrolling
Updated:  12/31/1969
UMass Medical School
mi
from
Worcester, MA
Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Status: Enrolling
Updated: 12/31/1969
UMass Medical School
mi
from
Worcester, MA
Click here to add this to my saved trials
Patient and Family Partners in Heart Failure Care: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement During Medical Visits
Patient and Family Partners in Heart Failure: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement of Heart Failure Patients and Family Members During Medical Visits
Status: Enrolling
Updated:  12/31/1969
UNC School of Medicine
mi
from
Chapel Hill, NC
Patient and Family Partners in Heart Failure Care: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement During Medical Visits
Patient and Family Partners in Heart Failure: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement of Heart Failure Patients and Family Members During Medical Visits
Status: Enrolling
Updated: 12/31/1969
UNC School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Status: Enrolling
Updated:  12/31/1969
Janssen Investigative Site
mi
from
Titusville, NJ
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Status: Enrolling
Updated: 12/31/1969
Janssen Investigative Site
mi
from
Titusville, NJ
Click here to add this to my saved trials
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
(RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
(RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
Mission Health and Hospitals
mi
from
Asheville, NC
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
Mission Health and Hospitals
mi
from
Asheville, NC
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
Main Line Health Center/Lankenau Hospital
mi
from
Wynnewood, PA
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
Main Line Health Center/Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Center
mi
from
Nashville, TN
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
CHI St. Luke's Health, Baylor College of Medicine
mi
from
Houston, TX
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
CHI St. Luke's Health, Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated:  12/31/1969
Cliniques Universitaires Saint Luc
mi
from
Brussels,
Trifecta™ GT Post Market Clinical Follow-up
Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)
Status: Enrolling
Updated: 12/31/1969
Cliniques Universitaires Saint Luc
mi
from
Brussels,
Click here to add this to my saved trials
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Statesville, NC
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye Ear Nose & Throat Associates, P.A.
mi
from
Statesville, NC
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
Tucson Vascular Surgery, PLLC
mi
from
Tucson, AZ
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
Tucson Vascular Surgery, PLLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
University of Arizona - UMC
mi
from
Tucson, AZ
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
University of Arizona - UMC
mi
from
Tucson, AZ
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
VA Hospital
mi
from
Little Rock, AR
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
VA Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
Palomar Hospital
mi
from
Escondido, CA
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
Palomar Hospital
mi
from
Escondido, CA
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
Long Beach VA Healthcare System
mi
from
Long Beach, CA
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
Long Beach VA Healthcare System
mi
from
Long Beach, CA
Click here to add this to my saved trials
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
The (PIVOTAL) Study
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials